Apixaban Dosing for Cerebral Venous Sinus Thrombosis
For this 56-year-old man with thrombosis of the sigmoid sinus, transverse sinus, and internal jugular vein, apixaban should be dosed at 10 mg orally twice daily for the first 7 days, followed by 5 mg twice daily for at least 3-6 months, with consideration for extended anticoagulation thereafter.
Initial Treatment Phase (First 7 Days)
The FDA-approved dosing for venous thromboembolism (VTE) treatment is 10 mg orally twice daily for 7 days 1. This higher initial dose is critical for acute thrombus treatment and differs fundamentally from atrial fibrillation dosing. Cerebral venous sinus thrombosis (CVST) is treated as a VTE, not as atrial fibrillation, so VTE-specific dosing must be used 2.
Maintenance Phase (After Day 7)
After the initial 7-day period, transition to 5 mg orally twice daily 1. This is the standard maintenance dose for VTE treatment and should continue for the primary treatment period.
Dose Reduction Criteria
Reduce to 2.5 mg twice daily ONLY if the patient meets at least 2 of these 3 criteria:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL (or creatinine clearance 15-50 mL/min)
Your 56-year-old patient does not meet age criteria, so dose reduction would only apply if he has both low body weight AND renal impairment. Do not empirically reduce the dose without meeting these specific criteria, as underdosing increases thrombotic risk 4.
Duration of Anticoagulation
Minimum Treatment Duration
Continue full-dose anticoagulation for at least 3-6 months as the primary treatment phase 5, 6. CVST is considered an unprovoked VTE unless there's a clear transient provoking factor (recent surgery, trauma, infection).
Extended Anticoagulation Consideration
After 6 months, strongly consider extended anticoagulation given this is likely unprovoked thrombosis 5. For extended therapy beyond 6 months, you have two options:
The reduced dose (2.5 mg twice daily) for extended therapy is supported by evidence showing it maintains efficacy while potentially reducing bleeding risk 5, 6. This decision should be reassessed annually, weighing recurrent thrombosis risk against bleeding risk 5.
Critical Implementation Points
Avoid common pitfalls:
- Do not use atrial fibrillation dosing (5 mg twice daily from the start) - this underdoses the acute phase 2
- Do not reduce dose based solely on bleeding concerns without meeting specific criteria 4
- Do not use warfarin dosing strategies (INR 2.0-2.5) - these are irrelevant for apixaban 2
Renal function monitoring: Check creatinine clearance before starting and periodically during treatment. If CrCl falls below 15 mL/min, apixaban data is limited and alternative anticoagulation may be needed 7, 8.
No bridging required: Unlike warfarin, apixaban has rapid onset of action, so no heparin bridging is needed when initiating therapy 3.
Evidence Quality Note
While the FDA label and major guidelines provide clear VTE dosing 1, 2, specific CVST data with apixaban is limited to case reports and series 9, 10, 11. However, CVST is managed as VTE per consensus, making the VTE dosing regimen the appropriate standard of care. The case series show successful outcomes with this approach 10, 11.